GPP
IGMS

Great Point Partners’s IGM Biosciences IGMS Stock Holding History

Great Point Partners’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-615,317
Closed -$5.14M – 42
2023
Q3 		$5.14M Buy
615,317
+115,317
+23% +$978K 0.94% 31
2023
Q2 		$4.62M Buy
+500,000
New +$5.6M 0.9% 31

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Great Point Partners's IGMS Position: Q4 2023 in Review

Great Point Partners sold out of IGM Biosciences (IGMS) in Q4 2023, closing a stake of 615,317 shares — an estimated $5.14M sold.

Great Point Partners first reported a position in IGMS in Q2 2023 and held it in 2 quarters. The position peaked at $5.14M in Q3 2023. 72 funds tracked by Wall St. Rank hold IGMS as of Q4 2023.

  • Great Point Partners reported no remaining IGM Biosciences position as of Q4 2023 after selling out during the quarter.
  • Great Point Partners sold 615,317 IGM Biosciences shares in Q4 2023, an estimated $5.14M.
  • Great Point Partners first reported a position in IGM Biosciences in Q2 2023 and held it in 2 quarters.
  • Great Point Partners's IGM Biosciences position peaked at $5.14M in Q3 2023.
  • 72 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2023.

Based on Great Point Partners's 13F filing for Q4 2023, filed 14 Feb 2024.